US 12,391,928 B2Granted

Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A

AssigneeResearch Institute At Nationwide Children's Hospital

InventorZarife Sahenk

Life of this patent

Estimating the term…

Abstract

Products and methods for treating limb girdle muscular dystrophy 2A are provided. In the methods, recombinant adeno-associated viruses deliver DNA encoding a protein with calpain 3 activity.

Claims4

Dependent claims

A recombinant adeno-associated virus (rAAV) comprising a polynucleotide which comprises nucleotides 1 to 3977 of SEQ ID NO:

1, wherein the rAAV comprises an AAV-8, an AAV-9, or an AAV rh.74 capsid protein, or a variant of each thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/255,488Filed 28 Jun 2019 · us provisional application
Priority: 29 Jun 2018
Published: US 2021/0277362 A19 Sep 2021
Granted: 19 Aug 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12N 7/00
Viruses
A61K 48/0058
Characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered: nucleic acids adapted for tissue…
A61P 21/00
Drugs for disorders of the muscular or neuromuscular system
C12N 9/6472
From mammals: cysteine endopeptidases

Family

Application62/691,934Us provisional application · filed 29 Jun 2018
Application62/865,081Us provisional application · filed 21 Jun 2019
US 2021/0277362 A1Pre-grant publication · published 9 Sep 2021
US 12,391,928 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results